Literature DB >> 12777089

Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases.

B Benyahia1, Z Amoura, A Rousseau, C Le Clanche, A Carpentier, J C Piette, J Y Delattre.   

Abstract

Sera from 71 patients with primary Sjögren's syndrome (PSS) and from 102 patients with systemic lupus erythematosus (SLE) were tested by immuno-dot blotting against HuD, Ri, Yo and amphiphysin recombinant proteins. For Ri, Yo and amphiphysin antigens, no immunoreactivity was found in the 173 sera tested. One PSS patient with a clinical picture of subacute sensory neuronopathy had high titers of anti-Hu antibodies. An extensive search for an underlying tumor was initially negative but a small cell lung cancer was eventually discovered three years later. Another patient with SLE and a clinical picture of demyelinating polyradiculoneuropathy had anti-Hu antibodies. Repeated search for an underlying tumor remains negative after five years follow-up in this young non-smoking patient. In addition, the neuropathy progressively improved and the anti-Hu antibodies titer slowly decreased from 1:8000 to 1:2000, making the diagnosis of paraneoplastic syndrome unlikely in this patient. This study indicates that the detection of anti-Hu antibodies in patients with known symptomatic systemic autoimmune diseases such as PSS or SLE should induce the same work-up than the detection of these antibodies in the absence of other immune diseases, i.e. repeated search for occult cancer during several years. As illustrated by our first patient, this strategy may be fruitful. Nevertheless, the clinician should know that anti-Hu antibodies may exceptionally (0.6% in this series) occur in systemic autoimmune disorders with neurological complications, in the absence of an underlying neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12777089     DOI: 10.1023/a:1023396020559

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

1.  Systemic lupus erythematosus with anti-Hu antibodies and polyradiculoneuropathy.

Authors:  A F Carpentier; B Chassande; Z Amoura; B Benyahia; J C Piette; J Y Delattre
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; J Coll; R Gerli; P Y Hatron; L Kater; Y T Konttinen; R Manthorpe; O Meyer; M Mosca; P Ostuni; R A Pellerito; Y Pennec; S R Porter; A Richards; B Sauvezie; M Schiødt; M Sciuto; Y Shoenfeld; F N Skopouli; J S Smolen; F Soromenho; M Tishler; M J Wattiaux
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

4.  Spontaneous neurological improvement in anti-Hu associated encephalomyelitis.

Authors:  T Byrne; W P Mason; J B Posner; J Dalmau
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  Peripheral neuropathy in systemic lupus erythematosus.

Authors:  C Huynh; S L Ho; K Y Fong; R T Cheung; C C Mok; C S Lau
Journal:  J Clin Neurophysiol       Date:  1999-03       Impact factor: 2.177

6.  Neurologic complications of primary Sjögren's syndrome.

Authors:  E L Alexander; T T Provost; M B Stevens; G E Alexander
Journal:  Medicine (Baltimore)       Date:  1982-07       Impact factor: 1.889

7.  Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.

Authors:  C F Lucchinetti; D W Kimmel; V A Lennon
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

8.  Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites.

Authors:  G T Manley; P S Smitt; J Dalmau; J B Posner
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

9.  Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease.

Authors:  P Sillevis-Smitt; G Manley; J W Moll; J Dalmau; J B Posner
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

10.  Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies.

Authors:  R B Darnell; L M DeAngelis
Journal:  Lancet       Date:  1993-01-02       Impact factor: 79.321

  10 in total
  3 in total

1.  Hu-antibody-positive patients with or without cancer have similar clinical profiles.

Authors:  A Lladó; A F Carpentier; J Honnorat; P Sillevis-Smitt; A Twijnstra; Y Blanco; I K Hart; A Saiz; F Graus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-08       Impact factor: 10.154

2.  Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases.

Authors:  Lucinda Aguirre-Cruz; Jean-Luc Charuel; Antoine F Carpentier; Baya Benyahia; Jean-Yves Delattre; Lucile Musset
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

3.  Sensory neuronopathy and autoimmune diseases.

Authors:  Alberto R M Martinez; Marcelo B Nunes; Anamarli Nucci; Marcondes C França
Journal:  Autoimmune Dis       Date:  2012-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.